Oxidative Stress in Polycystic Ovary Syndrome
Launched by MARDIN ARTUKLU UNIVERSITY · Feb 10, 2025
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • The PCOS group included patients with oligomenorrhea (menstrual period intervals of more than 35 days), clinical signs of hyperandrogenism (acne or hirsutism), biochemical signs of hyperandrogenism (with total testosterone of 100 ng/dL and above and patients with dehydroepiandrosterone sulfate of 400 g/dl and above), an LH/FSH ratio of over 3 on the second day of the menstrual period, a body mass index of 25 and above, and polycystic ovaries detected in suprapubic ultrasonography.
- Exclusion Criteria:
- • Pregnant individuals, individuals with diabetes mellitus, metabolic syndrome, adrenal pathology, pelvic mass, and malignancy were not included in the study.
About Mardin Artuklu University
Mardin Artuklu University is a distinguished academic institution committed to advancing research and education in various fields, including health sciences. As a clinical trial sponsor, the university leverages its expertise and resources to facilitate innovative research initiatives aimed at improving patient outcomes and enhancing medical knowledge. With a focus on ethical standards and scientific rigor, Mardin Artuklu University fosters collaboration among researchers, healthcare professionals, and industry partners to drive impactful clinical studies that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Antalya, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported